News 23andMe stock sell-off adds to its woes Shares in genetic testing company 23andMe continue to slide after prominent investors announce plans to sell their stakes
News 23andMe ends drug development and slashes staff 23andMe's big push into drug development, announced with great fanfare almost a decade ago, has ended with a whimper and sweeping job losses.
News 23andMe board rebuffs CEO plan to take the firm private A proposal by 23andMe founder and chief executive Anne Wojcicki to take the genetic testing company private has been rejected by a special committee of the board of directors.
Patients Genetic testing update with 23andMe’s Noura Abul-Husn In the latest instalment of the pharmaphorum podcast, editor-in-chief Jonah Comstock is joined by Dr Noura Abul-Husn, VP of genomic health at 23andMe.
News 23andMe, Novartis team up to put Lp(a) on patients’ radar Lipoprotein(a) is well established as a risk factor for cardiovascular disease, but patients rarely get tested for it.
News 23andMe doses first patient in ph2a anti-tumour monotherapy Additionally, the company will be making investor presentations today and next week.
News Daiichi and AZ pull Dato-DXd filing in Europe too AstraZeneca and Daiichi Sankyo have decided to voluntarily withdraw their EU marketing application for Dato-DXd in lung cancer.
Digital Sponsored The AI effect in pharma commercial strategy: From data to re... Discover how AI is transforming the pharma commercial strategy. Unlock real-time insights & actions from data. Click here for more.
